BC Extra | Oct 31, 2015
Company News

Management tracks

Baxter International Inc. (NYSE:BAX) said Jose Almeida will replace the retiring Robert Parkinson as chairman and CEO, effective Jan. 1, 2016. Almeida was chairman, president and CEO of Covidien plc , which Medtronic plc (NYSE:MDT) acquired....
BioCentury | Apr 6, 2015
Emerging Company Profile

Treating H. pylori

ImevaX GmbH is developing a therapeutic vaccine against Helicobacter pylori that could be more effective than standard of care without generating resistance. The company also is developing two diagnostics for the bacterial infection, including a...
BC Week In Review | Mar 9, 2015
Financial News

ImevaX financial update

ImevaX GmbH , Munich, Germany   Business: Infectious   Date announced: 2015-03-02   Note: ImevaX raised EUR500,000 ($559,650) in a second close of a series A, bringing the total raised in the round to EUR8 million...
BC Innovations | Feb 26, 2015
Finance

Europe waking to the American dream

While Europe didn't see the spike in seed and series A financing that the U.S. biotech sector enjoyed in 2014, there are signs the region is beginning to capitalize on the strength of its academic...
BC Innovations | Feb 5, 2015
Finance

PPPs holding steady

BioCentury's annual analysis of public-private partnerships and early stage venture financing activity shows that the model of using PPPs to foster academic innovation is holding fast, and that academia is an active driver behind the...
BC Week In Review | Dec 8, 2014
Company News

ImevaX, Technical University Munich infectious news

The university spun out ImevaX to develop vaccines against pathogens of chronic and nosocomial infectious disease. ImevaX’s lead candidate, IMX101 , is a recombinant vaccine against Helicobacter pylori infection that is in preclinical testing. ImevaX GmbH...
BC Week In Review | Nov 24, 2014
Financial News

ImevaX completes venture financing

ImevaX GmbH , Munich, Germany   Business: Infectious   Date completed: 2014-10-28   Type: Venture financing   Raised: EUR7.5 million ($9.5 million)   Investors: Wellington Partners; BioMedInvest; BioMedPartners; EMBL Ventures; Santo Venture Capital  ...
BC Week In Review | Dec 9, 2013
Company News

ImevaX, ProJect Pharmaceutics deal

ProJect and ImevaX partnered to develop a formulation of ImevaX's IMX101 vaccine against Helicobacter pylori infection. The partners will use ProJect's predictive formulation analytics technology, which optimizes protein formulations by determining the most favorable composition...
Items per page:
1 - 8 of 8
BC Extra | Oct 31, 2015
Company News

Management tracks

Baxter International Inc. (NYSE:BAX) said Jose Almeida will replace the retiring Robert Parkinson as chairman and CEO, effective Jan. 1, 2016. Almeida was chairman, president and CEO of Covidien plc , which Medtronic plc (NYSE:MDT) acquired....
BioCentury | Apr 6, 2015
Emerging Company Profile

Treating H. pylori

ImevaX GmbH is developing a therapeutic vaccine against Helicobacter pylori that could be more effective than standard of care without generating resistance. The company also is developing two diagnostics for the bacterial infection, including a...
BC Week In Review | Mar 9, 2015
Financial News

ImevaX financial update

ImevaX GmbH , Munich, Germany   Business: Infectious   Date announced: 2015-03-02   Note: ImevaX raised EUR500,000 ($559,650) in a second close of a series A, bringing the total raised in the round to EUR8 million...
BC Innovations | Feb 26, 2015
Finance

Europe waking to the American dream

While Europe didn't see the spike in seed and series A financing that the U.S. biotech sector enjoyed in 2014, there are signs the region is beginning to capitalize on the strength of its academic...
BC Innovations | Feb 5, 2015
Finance

PPPs holding steady

BioCentury's annual analysis of public-private partnerships and early stage venture financing activity shows that the model of using PPPs to foster academic innovation is holding fast, and that academia is an active driver behind the...
BC Week In Review | Dec 8, 2014
Company News

ImevaX, Technical University Munich infectious news

The university spun out ImevaX to develop vaccines against pathogens of chronic and nosocomial infectious disease. ImevaX’s lead candidate, IMX101 , is a recombinant vaccine against Helicobacter pylori infection that is in preclinical testing. ImevaX GmbH...
BC Week In Review | Nov 24, 2014
Financial News

ImevaX completes venture financing

ImevaX GmbH , Munich, Germany   Business: Infectious   Date completed: 2014-10-28   Type: Venture financing   Raised: EUR7.5 million ($9.5 million)   Investors: Wellington Partners; BioMedInvest; BioMedPartners; EMBL Ventures; Santo Venture Capital  ...
BC Week In Review | Dec 9, 2013
Company News

ImevaX, ProJect Pharmaceutics deal

ProJect and ImevaX partnered to develop a formulation of ImevaX's IMX101 vaccine against Helicobacter pylori infection. The partners will use ProJect's predictive formulation analytics technology, which optimizes protein formulations by determining the most favorable composition...
Items per page:
1 - 8 of 8